Dr. Juric is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-726-6500Fax+1 617-724-1079
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2009
University of Zagreb Faculty of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2011 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Start of enrollment: 2012 Mar 01
- Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer Start of enrollment: 2012 Sep 21
- BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden
Clinical Cancer Research. 2025-01-02 - Financial toxicity in early-phase cancer clinical trial participants.Sienna M Durbin, Debra Lundquist, Andrea Pelletier, Laura A Petrillo, Viola Bame
Cancer. 2025-01-01 - 139 citationsAlpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre...Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego
The Lancet. Oncology. 2024-12-01
Press Mentions
Evaluating Inavolisib vs Alpelisib plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast CancerSeptember 24th, 2024- Remembering JoséMarch 30th, 2021
- How Targeted Therapies Are Changing the Breast Cancer Treatment LandscapeMarch 26th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
